Repository logo
 
Publication

Transfection of pulmonary cells by stable pDNA-polycationic hybrid nanostructured particles

dc.contributor.authorGaspar, Diana P.
dc.contributor.authorVital, Joana
dc.contributor.authorLeiva, María C.
dc.contributor.authorGonçalves, Lídia M. D.
dc.contributor.authorTaboada, Pablo
dc.contributor.authorRemuñán-López, Carmen
dc.contributor.authorVítor, Jorge M. B.
dc.contributor.authorAlmeida, António J.
dc.date.accessioned2023-05-18T18:53:48Z
dc.date.available2023-05-18T18:53:48Z
dc.date.issued2019-02
dc.date.updated2022-10-19T21:20:56Z
dc.description.abstractAim: Cationically modified solid lipid nanoparticles (SLN) were investigated as plasmid DNA (pDNA) carriers and transfection agents for the pulmonary route. Materials & methods:pDNA-loaded SLN were produced using glyceryl dibehenate or tristearate as matrix lipids and chitosan as surface charge modifier, and encapsulated by spray-drying in mannitol and trehalose microspheres. Results: Nanoparticles of 200 nm, and zeta potential around +15 mV were produced. Electrophorectic analysis confirmed plasmid stability and integrity. The pDNA-loaded SLN were able to transfect the Calu-3 and A549 pulmonary cell lines, while showing low cytotoxicity. Microencapsulation of SLN yielded dry powders suitable for inhalation that protected pDNA from degradation. Conclusion: Microencapsulated SLN are a promising safe and effective carrier system for pulmonary gene delivery following pulmonary administration.pt_PT
dc.description.sponsorshipThis work was supported by Fundação para a Ciência e Tecnologia, Portugal (projects UID/DTP/04138/2013 and PTDC/DTP-FTO/0094/2012, and grants SFRH/BD/89520/2012 and SFRH/BSAB/1210/2011). This work was also supported by Spanish Government (PN de I+D 2008-2011, ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, Acción Estratégica de Salud, Projects FIS, PS09/00816, and MAT2013-40971-R), Xunta de Galicia (Project Competitive Reference Groups-FEDER Funds Ref. 2014/043 and Project Competitive Emergent Groups-FEDER Funds EM2013-046). Jorge Vitor's lab has been financed by New England Biolabs, Inc. (USA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.2217/nnm-2018-0270pt_PT
dc.identifier.issn1743-5889
dc.identifier.issn1748-6963
dc.identifier.slugcv-prod-314981
dc.identifier.urihttp://hdl.handle.net/10451/57469
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFuture Medicinept_PT
dc.relationPTDC/DTPFTO/ 0094/2012pt_PT
dc.relationResearch Institute for Medicines
dc.relationMICROENCAPSULATED LIPID NANOPARTICLES FOR PULMONARY DELIVERY OF BIOPHARMACEUTICAL AGENTS
dc.relationNEW SRATEGIES FOR ANTIGEN AND PROTEIN DELIVERY USING NANOBIOMATERIALS
dc.relation.publisherversionhttps://www.futuremedicine.com/doi/10.2217/nnm-2018-0270pt_PT
dc.subjectChitosanpt_PT
dc.subjectGene deliverypt_PT
dc.subjectInhalationpt_PT
dc.subjectMicroencapsulationpt_PT
dc.subjectPlasmidpt_PT
dc.subjectSolid lipid nanoparticlespt_PT
dc.subjectSpray-dryingpt_PT
dc.titleTransfection of pulmonary cells by stable pDNA-polycationic hybrid nanostructured particlespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleResearch Institute for Medicines
oaire.awardTitleMICROENCAPSULATED LIPID NANOPARTICLES FOR PULMONARY DELIVERY OF BIOPHARMACEUTICAL AGENTS
oaire.awardTitleNEW SRATEGIES FOR ANTIGEN AND PROTEIN DELIVERY USING NANOBIOMATERIALS
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID%2FDTP%2F04138%2F2013/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/OE/SFRH%2FBD%2F89520%2F2012/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/PIDDAC/SFRH%2FBSAB%2F1210%2F2011/PT
oaire.citation.conferencePlaceReino Unidopt_PT
oaire.citation.endPage429pt_PT
oaire.citation.issue4pt_PT
oaire.citation.startPage407pt_PT
oaire.citation.titleNanomedicinept_PT
oaire.citation.volume14pt_PT
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStreamOE
oaire.fundingStreamPIDDAC
person.familyNameDiogo Gonçalves
person.familyNameVítor
person.familyNameLeitão das Neves Almeida
person.givenNameLídia Maria
person.givenNameJorge
person.givenNameAntónio José
person.identifierI-6590-2012
person.identifier.ciencia-id7211-22BA-86AD
person.identifier.ciencia-idFF19-99F4-3964
person.identifier.ciencia-id8312-F853-C47A
person.identifier.orcid0000-0002-6799-2740
person.identifier.orcid0000-0001-6486-3444
person.identifier.orcid0000-0002-7807-4726
person.identifier.ridM-3279-2013
person.identifier.scopus-author-id7801493621
person.identifier.scopus-author-id57195052432
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.cv.cienciaidFF19-99F4-3964 | Jorge Manuel Barreto Vítor
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication3265148d-dc2d-4601-a832-2e72f7be5662
relation.isAuthorOfPublicationbe15e90f-9cc9-4ad0-b9fd-465236b72e9a
relation.isAuthorOfPublicationdab457ee-7a1d-4c3d-a906-1e8df92fffd6
relation.isAuthorOfPublication.latestForDiscoverydab457ee-7a1d-4c3d-a906-1e8df92fffd6
relation.isProjectOfPublication9d71fb66-d168-40b8-9f2c-b0127783ea17
relation.isProjectOfPublicationd2e3b983-f8df-4c78-84f1-224fa56539f9
relation.isProjectOfPublication42a2988f-b282-4132-bd81-17ab51b266bd
relation.isProjectOfPublication.latestForDiscoveryd2e3b983-f8df-4c78-84f1-224fa56539f9

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
nnm-2018-0270-2.pdf
Size:
19.53 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.2 KB
Format:
Item-specific license agreed upon to submission
Description: